1 Smith MA, Nunomura A, Lee HG, Zhu X, Moreira PI, Avila J, et al.Chromological primacy of oxidative stress in Alzhei-mer's disease[J]. Neurobiol Aging, 2005;26:587-95
2 Nicolas G.Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2(USF2)knockout mice[J]. Proc Natl Acad Sci USA, 2001;98:8780-5
3 Christen Y.Oxidative stress and Alzheimer disease[J]. Am J Clin Nutr, 2000;71:621-9
4 Da la Monte SM.Oxygen free radical injury is sufficientto cause some Alzheimer-type molecula abnormalities in humanCNS neu-ronal cell[J]. J Alzheimr Dis, 2000;2:261-81
5 Maiese K, Chong ZZ.Insights into oxidative stress and potential novel therapeutic targets for Alzheimer disease[J]. Restor Neu-rolNeurosci, 2004;22:87-104
6 Da la Monte SM, Neely TR, Cannon J, Wands JR.Oxidative stress and hypoxia-like injury cause Alzheimer-type molecular abnormalities in central nervous system neurons[J]. Cell Mol Life Sci, 2000;57:1471-81
7 Apelt J, Bigl M, Wunderlich P, Schliebs R.Aging-related in-crease in oxidative stress correlateswith developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576mice with Alzheimer-like pathology[J]. Int J Dev Neurosci, 2004;22:475-84
8 Schoneich C, Pogocki D, Hug GL, Bobrowski K.Free radical reactions of methionine in peptides:mechanisms relevant to be-ta-amyloid oxidation and Alzheimer's disease[J]. J Am Chem Soc, 2003;125:13700-13
9 Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, et al.Rationale anddesign of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes.Alzheimer's disease coo-perative study[J]. Alzheimer Dis Assoc Disord, 1996;10:132-40
10 Grundman M.Vitamin E and Alzheimer's disease:the basis for additional clinical trials[J]. Am J ClinNutr, 2000;71:630-6
11 Rrlt S, Kontush A, Muller-Thomsen.Lipoproteinoxidation as a common pathomechanism in coronary heart disease and Alzhei-mer disease[J]. Z Gerontol Geriatr, 2001;34:461-7
12 Zheng F, Zhang JT.Melatonin reduces amyloidβ-induced ap-optosis in pheochromacytoma(PC12)cell[J]. J Pineal Res, 2004;37:257-66
13 Etsuro M, Tara Bryant -Thomas, Javier PQ, Tracey LH, Burkhard P, Donald H, et al.Melatonin in increases survival and inhibits oxidative and amyloid pathology in a transgenic model ofAlzheimer'sdisease[J]. JNeurochemistry, 2003;85: 1101-8
14 Feng Z, Chang Y, Cheng Y, Zhang BL, Qu ZW, Qin C, et al.Melatonin alleviates behavioral deficits associated with ap-optosis and cholinergic system dysfunction in the APP 695 trans-genic mouse model of Alzheimer's disease[J]. J Pineal Res, 2004;37:129-36
15 Choi YT, Jung CH, Lee SR, Bae JH, Baek WK, Suh MH, et al.The green tea polyphenol(-)-epigallocatechin gallate atten-uates beta-amyloid-induced neurotoxicity in cultured hippocam-pal neurons[J]. Life Sci, 2001;70:603-14
16 Lee L, Bae JH, Lee SR.Protective effect of green tea polyphe-nol EGCG against neuronal damage and brain edema after uni-lateral cerebral ischemia in gerbils[J]. J Neurosci Res, 2004; 77:892-900
17 Qin XS, Jin KH, Ding BK, Xie SF, Ma H.Effects of extract of Ginkgo biloba with venlafaxine onbrain injury in a rat mode-lof depression[J]. ChinMed J, 2005;118:391-7
18 Kim MS, Lee JI, Lee WY, Kim SE.Neuroprotective effect of Ginkgobiloba L.extract in a rat model of Parkinson's disease [J]. Phytother Res, 2004;18:663-6
19 NiittykoskiM, Haapalinna A, Sirvio J.Selegiline reduces N-methyl -D-aspartic acid induced perturbation of neurotransmis-sion but it leavesNMDA receptor dependent long-term potentia-tion intact in the hippocampus[J]. J Neural Transm, 2003; 110:1225-40
20 Carageorgiou H, ZarrosA, TsakirisS.Selegiline long-term ef-fects on brain acetylcholinesterase, (Na+-,K+)-ATPase activi-ties, antioxidant status and learning performance of aged rats [J]. Pharmacol Res, 2003;48:245-51 |
